Immunogenicity, Tolerability, and Clinical Effectiveness of 23-Valent Polysaccharide Pneumococcal Vaccine in Patients with Systemic Lupus Erythematosus

The aim of the work is to study the immunogenicity, tolerability, and clinical efficacy of the 23-valent polysaccharide pneumococcal vaccine (PPV-23) in patients with systemic lupus erythematosus (SLE). Material and methods. The study included 61 patients with a confirmed diagnosis of SLE, including...

Full description

Bibliographic Details

Published in:	Антибиотики и Химиотерапия
Main Authors:	G. M. Tarasova, B. S. Belov, M. V. Cherkasova, S. K. Soloviev, E. A. Aseeva, T. M. Reshetnyak, T. V. Popkova, N. M. Kosheleva
Format:	Article
Language:	Russian
Published:	LLC "Publishing House OKI" 2020-08-01
Subjects:	systemic lupus erythematosus pneumonia vaccination 23-valent polysaccharide pneumococcal vaccine immunosuppressive therapy genetically engineered biological drugs
Online Access:	https://www.antibiotics-chemotherapy.ru/jour/article/view/738